^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | carboplatin (Tubulin polymerization promoter) + gemcitabine (DNA synthesis inhibitor) + Rituxan (rituximab) (CD20 inhibitor) + dexamethasone (GCR agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/20/2021
Excerpt:
Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Preferred Regimens…GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab
